Hospital Readmissions in Patients With Carbapenem-Resistant <span class="italic">Klebsiella pneumoniae</span> by Messina, Julia A. et al.
Hospital Readmissions in Patients with Carbapenem-Resistant 
Klebsiella pneumoniae
Julia A. Messina, M.D., M.Sc.1,2, Eric Cober, M.D.3, Sandra S. Richter, M.D.4, Federico 
Perez, M.D.5,6, Robert A. Salata, M.D.6, Robert C. Kalayjian, M.D.7, Richard R. Watkins, M.D.
8,9, Nikole M. Scalera, M.D10, Yohei Doi, M.D., Ph.D.11, Keith S. Kaye, M.D.12, Scott Evans, 
Ph.D.13, Robert A. Bonomo, M.D.5,6,14,15, Vance G. Fowler Jr., M.D., M.H.S.1,2, and David 
van Duin, M.D., Ph.D.16,* for the Antibacterial Resistance Leadership Group
1Division of Infectious Diseases, Duke University, Durham, North Carolina, United States of 
America
2Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States of 
America
3Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, United States of America
4Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America
5Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 
Cleveland, Ohio, United States of America
6Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western 
Reserve University School of Medicine, Cleveland, Ohio, United States
7Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio, United States of 
America
8Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, Ohio United 
States of America
9Division of Infectious Diseases, Akron General Medical Center, Akron, Ohio, United States of 
America
10Division of Infectious Diseases, Summa Health System, Akron, Ohio, United States of America
11Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, 
Pennsylvania
*Corresponding author: David van Duin, MD, PhD, Division of Infectious Diseases, CB 7030, University of North Carolina, 130 
Mason Farm Road, Chapel Hill, North Carolina 27599, United States of America, Telephone: 919-843-2200, Fax: 919-966-6714, 
david_vanduin@med.unc.edu. 
Preliminary results from this study were presented at IDWeek; October 8-12, 2014, Philadelphia, Pennsylvania, USA.
Disclaimer. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National 
Institutes of Health.
Conflict of Interest:
No potential conflicts: J.A.M, E.C., F.P., R.A.S., R.C.K., R.R.W., N.M.S., and S.E.
Potential conflicts of interest:
All other authors: no conflicts reported
HHS Public Access
Author manuscript
Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2017 March 01.
Published in final edited form as:













12Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, 
Michigan, United States of America
13Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard School 
of Public Health, Boston, Massachusetts, United States of America
14Department of Molecular Biology and Microbiology, Case Western Reserve University School of 
Medicine, Cleveland, Ohio, United States of America
15Department of Pharmacology, Case Western Reserve University School of Medicine, 
Cleveland, Ohio, United States of America
16Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, United 
States of America
Abstract
Background—Various transmission routes contribute to spread of Carbapenem-resistant 
Klebsiella pneumoniae (CRKP) in hospitalized patients. Patients with readmissions during which 
CRKP is again isolated (“CRKP readmission”) potentially contribute to transmission of CRKP.
Objective—Evaluate CRKP readmissions in the Consortium on Resistance against Carbapenems 
in K. pneumoniae (CRaCKle).
Design—Cohort study from 12/24/2011 to 7/1/2013
Setting—CRaCKle is a multicenter consortium of acute care hospitals in the Great Lakes region.
Patients—All patients who were discharged alive during the study period were included. Each 
patient was included only once at the time of the first CRKP positive culture.
Methods—All readmissions within 90 days of discharge from the index hospitalization during 
which CRKP was again found were analyzed. Risk factors for CRKP readmission were evaluated 
in multivariable models.
Results—Twenty percent of patients who were discharged alive (56/287) had a CRKP 
readmission. A history of malignancy was associated with CRKP readmission (aOR 3.00, 95% CI 
1.32-6.65, p<0.01). During the index hospitalization, 160 (56%) patients received antibiotic 
treatment targeted against CRKP. The choice of antibiotic regimen was associated with CRKP 
readmission (p=0.02). Receipt of tigecycline-based therapy (aOR 5.13, 95% CI 1.72-17.44, using 
aminoglycoside-based therapy as a reference in those treated with anti-CRKP antibiotics) was 
associated with CRKP readmission.
Conclusion—Hospitalized patients with CRKP – specifically those with a history of malignancy 
– are at high risk of readmission with recurrent CRKP infection or colonization, which may 
contribute to transmission of CRKP in healthcare systems. Treatment during the index 
hospitalization with a tigecycline-based regimen increases this risk.
Keywords
carbapenem resistant Enterobacteriaceae; Klebsiella pneumoniae; readmission; transmission; 
tigecycline
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In spite of aggressive treatment, carbapenem-resistant Klebsiella pneumoniae (CRKP) 
infections remain associated with high morbidity and mortality.1,2 Posing a global threat, 
CRKP are now endemic in areas worldwide including in the United States, Asia, India, 
Europe and South America.3 Klebsiella spp. expressing Klebsiella pneumoniae 
carbapenemases (KPC) are the most common carbapenem-resistant Enterobacteriaceae 
(CRE) in the United States and have increased rapidly in prevalence during the past two 
decades.4,5
The rising prevalence of CRKP impacts infection control policies within healthcare settings. 
KPC β-lactamases encoded by blaKPC may be acquired through both clonal and plasmid 
expansion, facilitating spread of carbapenem resistance among Enterobacteriaceae.6 
Various routes of transmission were demonstrated in recent CRKP outbreaks.7-9 Patients 
residing in long-term care facilities (LTCF) who are subsequently admitted to acute care 
hospitals are thought to significantly contribute to the transmission of CRKP. A recent study 
confirms that patients who are admitted to acute care hospitals from high-acuity LTCF are 
more likely to be colonized with KPC-producing Enterobacteriaceae.10
As hospital readmissions of patients with persistent or recurrent CRKP may contribute to the 
accelerated spread of this pathogen, rates of and risk factors for readmission in patients with 
CRKP during which the organism is again isolated are important to delineate. In order to 
better understand the manner in which CRKP is disseminated in the Great Lakes region, we 
sought to determine how often patients infected or colonized with CRKP were readmitted 
with repeat positive cultures for CRKP and whether the choice of treatment regimen directed 
against CRKP influenced CRKP readmission rates.
Patients and Methods
Design
A nested cohort study was conducted within the Consortium on Resistance against 
Carbapenems in Klebsiella pneumoniae (CRaCKle) cohort, which was previously 
described 11. Briefly, CRaCKle is a multicenter, prospective, longitudinal, observational 
study of hospitalized patients with positive cultures for CRKP in the Great Lakes Region. 
The cohort consists of CRaCKle patients who survived their index hospitalization and 
whose index hospitalization started after 12/24/2011 and ended on or before July 1, 2013. 
Routine screening of asymptomatic patients for CRKP carriage was not performed at any of 
the study sites during the study period. The Institutional Review Boards of all sites involved 
approved the study.
Definitions
The primary outcome of this study was CRKP readmission, which was defined as a hospital 
readmission within 90 days of the index hospitalization during which CRKP was again 
cultured from the patient. The index hospitalization was defined as the first hospitalization 
within the study period during which CRKP was identified. Each patient was included only 
once at the time of the index hospitalization.
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Standardized definitions of infection were used, as previously described.11 Treatment 
regimens effective against CRKP were defined as follows: receipt of an aminoglycoside, 
colistin, tigecycline, trimethoprim-sulfamethoxazole (TMP-SMX), or fosfomycin unless in 
vitro resistance was documented to that antimicrobial in the patient’s isolate. In all instances 
guidelines from the Clinical and Laboratory Standards Institute (aminoglycosides, TMP-
SMX, and fosfomycin) and the European Committee on Antimicrobial Susceptibility 
Testing (colistin and tigecycline) were followed. For analysis purposes, the type of regimen 
was assigned as previously reported.12 Briefly, any regimen which contained an 
aminoglycoside was deemed “aminoglycoside-based”, then any regimen that contained 
colistin but not an aminoglycoside was designated “colistin-based”, followed by any 
regimen that contained tigecycline but not colistin or aminoglycoside, was regarded as 
“tigecycline-based”. All other regimens were classified as “other”. Chronic kidney disease 
(CKD) was defined as a serum creatinine >2 mg/dL upon admission. Critical illness was 
designated using a Pitt bacteremia score greater or equal to 4 points on the day of the index 
culture.13 Charlson comorbidity index was calculated as described.14
Microbiology
In our study CRKP are K. pneumoniae isolates with non-susceptibility per CLSI guidelines 
to the following carbapenems: meropenem, imipenem, or ertapenem.15 Bacterial 
identification and routine antimicrobial susceptibility testing was performed with MicroScan 
(Siemens Healthcare Diagnostics) or Vitek2 (BioMerieux), supplemented by GN4F 
Sensititre tray (Thermo Fisher) or Etest (bioMerieux), as indicated. In more than 90% of 
tested isolates, carbapenem resistance was mediated through blaKPC-2 or blaKPC-3, as 
previously described.11
Statistical Analysis
Differences between groups were analyzed using Wilcoxon Rank Sum for continuous 
variables. Fisher’s Exact, and Pearson testing were used for categorical variables where 
appropriate. All variables that were associated with CRKP readmission at the p<0.1 level 
were included in multivariable logistic models, and adjusted odds ratios (aOR) with 
associated confidence intervals (CI) were calculated. A Kaplan-Meier curve was constructed 
to compare time to readmission. A Cox proportional hazards model on time to 90-day 
readmission was used to calculate adjusted hazard ratios (aHR). All variables that were 
associated with CRKP readmission at the p<0.1 level were included in this model in 
addition to treatment variables. P values of ≤0.05 were considered statistically significant. 
JMP 10.0.1 software (SAS, Inc, Cary, NC) was used for all analyses.
Results
Patients
The demographic characteristics of the 287 patients who met inclusion criteria are 
summarized in Table 1. CRKP infection was present during index hospitalization in 109 
(38%) patients, and the remaining 178 patients were classified as having CRKP 
colonization. During the index hospitalization, 192 (67%) patients had CRKP isolated from 
a urine sample, 32 (11%) patients had CRKP isolated from respiratory specimens, 30 (10%) 
Messina et al. Page 4













patients had CRKP isolated from wounds, 24 (8%) patients had CRKP isolated from blood, 
and 9 (3%) patients had CRKP isolated from “other” sites, which included abdominal 
sources such as bile, ascites, and abdominal abscess.
Fifty-six out of 287 (20%) patients had a readmission during which CRKP was again 
isolated (“CRKP readmission”) within 90 days. We evaluated 17 patients on whom we had 
paired isolates from index admission and readmission. In 16/17 (94%) of patients the same 
rep-PCR strain was identified upon readmission. During their readmission, 22 (39%) 
patients had CRKP infection while 34 (61%) patients had colonization of a site with CRKP 
(Table 1). In univariable analysis, CKD and history of malignancy were significantly 
associated with CRKP readmission within 90 days. Eighteen of 56 (32%) of patients with 
CRKP readmission had CKD as compared to 45/231 (19%) in patients without CRKP 
readmission (p=0.048). A history of malignancy was present in 12/56 (21%) of patients with 
CRKP readmission, as compared to 22/231 (10%) in others (p=0.02). In addition, a trend 
towards increased CRKP readmissions was seen in Black patients; thirty out of 56 patients 
with CRKP readmission (54%) were Black compared to 90/231 (39%) without CRKP 
readmission (p=0.051). In a multivariable model which included CKD, history of 
malignancy, and Black race, only a history of malignancy remained associated with CRKP 
readmission (OR 3.00, 95% CI 1.32-6.65, p<0.01). Gender, age, and CRKP colonization vs. 
infection status were not associated with CRKP readmission. In addition, a trend was seen 
towards more CRKP readmissions in patients with index isolates resistant to trimethoprim-
sulfamethoxazole was observed (p=0.07). Other antimicrobial susceptibility testing results 
were also not significantly associated with CRKP readmission (Table 2).
Treatment
During the index hospitalization, 160 (56%) patients received antibiotics directed against 
CRKP within the first 7 days of the first positive culture for CRKP. Being treated with 
antibiotics with in vitro activity against CRKP was not associated with CRKP readmission; 
30/56 (54%) of those with CRKP readmissions received some form of treatment, whereas 
130/231 (56%) of those without CRKP readmissions were treated (p=0.77).
The impact of specific treatment choices on CRKP readmissions was then evaluated in 
patients who received antibiotics effective against CRKP during their index hospitalization 
(Table 3). In univariable analysis, patients who received >1 drug with in vitro activity 
against CRKP were more likely to have a CRKP readmission; 13/42 (31%) of patients 
treated with more than one drug were readmitted versus 17/118 (14%) of patients treated 
with a single agent (OR 2.66, 95% CI 1.16-6.12, p=0.02). Most patients were treated with 
either an aminoglycoside-based regimen (n=70, 44%) or a tigecycline-based regimen (n=49, 
31%) during their index hospitalization. In patients with CRKP readmission, 14/30 (47%) 
were treated with a tigecycline-based regimen as compared to 35/130 (27%) in those without 
CRKP readmissions (OR 2.38, 95% CI 1.05- 5.37, p=0.047). When evaluating the receipt of 
tigecycline during the index hospitalization – regardless of other anti-CRKP antibiotics – a 
similar association between tigecycline use and CRKP readmission was observed (OR 2.64, 
95% CI 1.15-6.09, p=0.03). Fosfomycin use during the index hospitalization occurred in a 
total of 17 patients (11%) and was also associated with CRKP readmission in univariable 
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analysis (OR 3.65, 95% CI 1.26-10.58, p=0.02). In multivariable analysis (Table 4), regimen 
base remained significantly associated with CRKP readmission (p=0.02). Using patients 
who received aminoglycoside-based therapy as a reference group, the adjusted OR (aOR) of 
tigecycline-based therapy was 5.13 (95% CI 1.72-17.44). In addition, receipt of more than 
one anti-CRKP antibiotic during index hospitalization was strongly associated with CRKP 
readmission (aOR 5.14, 95% CI 1.78-16.41, p<0.01). When comparing patients who 
received more than one to those who received only one anti-CRKP antibiotic, no significant 
differences were found in age, Charlson comorbidity index, or Pitt bacteremia score.
Time to CRKP readmission
Tigecycline-based treatment was associated with a decreased time to 90-day CRKP 
readmission (p=0.04 by log-rank, Figure 1.A). Similarly, receiving any tigecycline – 
regardless of receipt of other antibiotics with in vitro activity against CRKP – was 
associated with decreased time to 90-day CRKP readmission (p=0.02 by log-rank, Figure 
1.B). In Cox proportional hazards analysis (Table 5), treatment regimen base remained 
significantly associated with time to 90-day CRKP readmission (p=0.02). Using the patients 
who received aminoglycoside-based therapy as a reference group, the aHR for tigecycline-
based therapy was 4.33 (95% CI 1.67-11.60). Of note, when urinary source was forced into 
the model as a confounding variable, the association between treatment regimen and time to 
CRKP readmission remained significant (data not shown). In addition, receipt of >1 in vitro 
active antibiotic in the first 7 days after the first positive CRKP culture during the index 
hospitalization was also associated with time to 90-day CRKP readmission (aHR 4.46, 95% 
CI 1.77-11.36; p<0.01). To determine if the association between tigecycline-based therapy 
and time to 90-day CRKP readmission was dependent on infection status during index 
hospitalization, a stratified analysis was performed. In both the CRKP colonization group as 
well as the CRKP infection group, treatment base was associated with time to 90-day CRKP 
readmission in Cox proportional hazard analysis (p=0.03 and p=0.04, respectively). The 
hazard ratios of tigecycline-based therapy, when using aminoglycoside-based therapy as a 
reference, were 3.99 (95% CI 1.20-14.31) and 6.56 (95% CI 1.39-34.81) for colonization 
and infection, respectively.
Discussion
The present study evaluates readmission rates with CRKP and analysis of risk factors from a 
prospective multicenter cohort. We observed that it was common for hospitalized patients 
with CRKP infection or colonization to have a readmission during which CRKP was again 
isolated. Interestingly, this occurred in 20% of patients who survived their index 
hospitalization. This finding suggests that patients with CRKP – especially those patients 
treated with tigecycline and those with a history of malignancy – carry CRKP for prolonged 
periods of time and have frequent and recurrent healthcare exposures during which they are 
likely to interact with other vulnerable patients. In contrast, the presence of CRKP infection 
vs. CRKP colonization did not appear to have an impact on CRKP readmission rates.
The observation of CRKP readmission is an outcome that requires two related but distinct 
occurrences. Firstly, the patient needs to be readmitted, and secondly, during that 
Messina et al. Page 6













readmission, CRKP must be cultured from a clinically important site. Thus, in the current 
study, we evaluated the overlapping risk factors for hospital readmission and prolonged 
CRKP carriage.
Hospital readmission rates are the subject of multiple studies to identify risk factors for 
readmission.16,17 Hospital reimbursement is increasingly being linked to readmission rates. 
In a recent report of 90-day readmissions following hospitalization for severe sepsis, the 
investigators noted a 42.6% readmission rate with 41.6% of these readmissions being for 
potentially preventable conditions such as heart failure exacerbation, pneumonia, and 
urinary tract infection.18 Potentially preventable readmissions occurred significantly more 
frequently in patients with severe sepsis compared to matched controls with other acute care 
diagnoses.
During a 90-day time period, a high rate of finding CRKP again during readmission was 
consistent with findings from studies of duration of CRE carriage. In one study, among 
patients who have CRE isolated during their index hospitalization, 78% of patients still had 
CRE carriage at 3 months while 39% still had detectable CRE carriage at 1 year.19 Those 
patients who were readmitted and in whom CRE was isolated in a clinical culture as 
opposed to a surveillance culture had significantly longer CRE carriage (641 days vs. 387 
days).19 Another study identified risk factors for recurrent positive CRE screens during 
hospital encounters including prior fluoroquinolone use, admission from another hospital or 
healthcare facility, and hospital readmission within 3 months of initial positive CRE 
screen.20 In a case-control study of recurrence of CRE carriage from Israel, recurrence of 
CRE was common after presumed eradication at 6 months after last positive sample and 
associated with recurrent admissions after presumed eradication.21
The current study did not directly address the role of CRE decolonization as a means to 
reduce the risk of future infection and spread of CRE to other patients. Decolonization is 
another potential target for infection control measures in high risk patients. In experimental 
models, oral high-dose polymyxin therapy resulted in long-term elimination of CRE 
carriage.22 This principle was then evaluated in a pilot study of selective digestive 
decontamination for eradication of CRKP carriage. A double blind randomized control trial 
was conducted in 40 patients comparing oral gentamicin and polymixin E versus placebo.23 
The investigators showed the CRKP isolation in rectal cultures was significantly reduced by 
2 weeks, and this reduction was maintained through the 6 week time period of the study.
Patients with malignancies were found to be at increased risk for CRKP readmission. This is 
likely secondary to an increased overall readmission risk in this cohort. In addition, cancer 
has been linked to microbiome changes24. This may theoretically influence the duration of 
CRKP carriage.
The finding of an increased risk of CRKP readmission when patients are treated with 
tigecycline raises concern for a potential relationship between tigecycline use and risk for 
subsequent CRKP treatment failure whether demonstrated through recurrent infection or 
persistent colonization. A number of potential explanations for this observed association 
could be considered. As this is an observational study, our data may simply reflect 
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confounding by indication. For some unmeasured reason, patients who are more likely to 
receive tigecycline may be the same patients who are more likely to get readmitted and have 
CRKP again isolated. Alternatively, this may represent a true association. Meta-analyses 
evaluating randomized controlled trials on the use of tigecycline in non-CRE infections are 
suggestive of inferior efficacy vs. comparators.25-28 Secondly, tigecycline is bacteriostatic 
rather than bacteriocidal and has a low urinary excretion. This antibiotic property likely 
plays an important role in this context; one wonders if the numbers of CRKP are not reduced 
sufficiently. Thirdly, current tigecycline dosing strategies (especially monotherapy) may not 
be optimal for treating multidrug-resistant bacteria such as CRKP.29 Lastly, tigecycline was 
also shown in murine models to promote the intestinal overgrowth of CRKP.22 In subgroup 
analysis, the association between tigecycline treatment and CRKP readmission was observed 
in both the group of patients with CRKP infection as well as the group with CRKP 
colonization.
Identifying risk factors for CRE isolation, infection, and readmission can potentially reduce 
patient-to-patient transmission of CRE within healthcare facilities. Multiple studies reported 
successful reduction in rates of epidemic CRE through targeted surveillance and infection 
control measures.30-33 Further study is needed to determine whether infection control 
measures such as routine culture screening, empiric contact isolation upon readmission, and 
standardized environmental cleaning protocols implemented in previous studies would be 
beneficial to patients at risk for CRE readmission.
Within the present study, receipt of more than one antibiotic with in vitro activity against 
CRKP in the first 7 days after a positive culture was also significantly associated with CRKP 
readmission. Our data cannot explain why this association was observed, but it is possibly 
related to reasons for adding or changing antibiotic regimens such as perceived failure of 
therapy or the occurrence of side effects. Alternatively, the use of several antibiotics may 
lead to increased disruption of the gut microbiome which in turn could lead to persistence of 
CRKP carriage. Similarly, antibiotic usage was linked to recurrence of CRE carriage in the 
case-control study by Bart et al.21
Limitations of this study include its observational nature; patients were not actively screened 
for CRKP on hospital admission, and antibiotic treatment was not randomized but based on 
clinical indication. As in all observational studies, we only can report on association rather 
than on causality. However, our study represents an inclusive cohort of consecutive patients 
admitted at various different hospitals being treated in a way that reflects current medical 
practice. Additionally, among patients who did not have a 90-day CRKP readmission, data 
was not collected beyond their index hospitalizations. Nonetheless, if patients were 
readmitted with CRKP during that time frame it is most likely that this readmission would 
have happened within the CRaCKle network and captured in our cohort, as the consortium 
covers most area hospitals.
In conclusion, we have established that in our population 20% of hospitalized patients with 
CRKP are readmitted within 90 days with repeat isolation from CRKP from clinical 
cultures. Interestingly, many of these isolates are the same strain as the index isolate. These 
patients contribute to the CRKP colonization pressure in acute care settings. Furthermore, 
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we found that a history of malignancy and choice of treatment impact this risk. Further 
studies in patients with CRE are needed to better characterize relationships between 
treatment, subsequent risk for readmission, duration of CRE carriage and risk for subsequent 
CRE infection. Moreover, identifying patients at risk for CRKP treatment failure and 
readmission and intervening through infection control measures and choice of treatment 
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Time-to-90-day CRKP readmission for patients who received anti-CRKP antibiotics 
(n=160) during their index hospitalization. Panel A: comparing patients who received 
tigecycline-based treatment during index hospitalization (n=49) vs. all others (n=111). Panel 
B: comparing patients who received any tigecycline during index hospitalization (n=76) vs. 
all others (n=84).
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N 287 56 (20) 231 (80)
Age, median (IQR) 70 (58-81) 69 (56-83) 70 (59-81) 0.73
Female 167 (58) 28 (50) 139 (60) 0.18
Race/Ethnicity
White 150 (52) 26 (46) 124 (54) 0.37
Black 120 (42) 30 (54) 90 (39) 0.051 0.06
Hispanic 8 (3) 0 8 (3) 0.36
Other 9 (3) 0 9 (4) 0.21
Charlson comorbidity
index, median (IQR)
3 (2-5) 3 (2-6) 3 (2-5) 0.40
Diabetes mellitus 153 (53) 28 (50) 125 (54) 0.65
Renal failure 
‡ 63 (22) 18 (32) 45 (19) 0.048 0.0922
Heart disease 160 (56) 28 (50) 132 (57) 0.37
COPD 77 (27) 15 (27) 62 (27) 1.00
Malignancy 23 (12) 12 (21) 22 (10) 0.02 <0.01
Origin 0.49
Skilled nursing facility 159 (55) 30 (53) 129 (56)
Home 84 (29) 20 (36) 64 (28)
Hospital transfer 28 (10) 3 (5) 25 (11)
Long term acute care 16 (6) 3 (5) 13 (6)
Length of stay, days,
median (IQR)
9 (6-16) 8 (6-16) 10 (6-16) 0.35
Critical illness 
§ 70 (24) 13 (23) 57 (25) 0.86
Infection 109 (38) 22 (39) 87 (38) 0.88
Source 0.46
Urine 192 (67) 41 (73) 151 (65)
Respiratory 32 (11) 4 (7) 28 (12)
Wound 30 (10) 7 (13) 23 (10)
Blood 24 (8) 2 (4) 22 (10)
Other 9 (3) 2 (4) 7 (3)
Any treatment 160 (56) 30 (54) 130 (56) 0.77
Disposition 0.51
Skilled nursing facility 157 (55) 28 (50) 129 (56)
Home 58 (20) 14 (25) 44 (19)
Hospital transfer 9 (3) 3 (5) 6 (3)
Long term acute care 63 (22) 11 (20) 52 (23)
All data expressed as n (%), unless otherwise indicated. IQR, interquartile range; LOS, length of stay.
*
univariable relationship between variable of interest and CRKP readmission
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†
multivariable model including black race, renal failure and malignancy
‡
renal failure defined as creatinine >2 mg/dL upon admission
§
critical illness defined as Pitt bacteremia score ≥4 at the time of index culture




















n 287 56 (20) 231 (80)
Amikacin*
not tested 89 15 (17) 74 (83)
susceptible 151 31 (21) 120 (79)
intermediate 10 0 10 (100)
resistant 37 10 (27) 27 (73)
Gentamicin*
not tested 2 0 2 (100)
susceptible 114 22 (19) 92 (81)
intermediate 25 6 (24) 19 (76)
resistant 146 28 (19) 118 (81)
Colistin
†
not tested 160 30 (19) 130 (81)
susceptible 117 25 (21) 92 (79)
resistant 10 1 (10) 9 (90)
Tigecycline
†
not tested 84 16 (19) 68 (81)
susceptible 107 25 (23) 82 (77)
intermediate 60 10 (17) 50 (83)
resistant 36 5 (14) 31 (86)
TMP/SMX*
not tested 9 0 9 (100)
susceptible 82 11 (13) 71 (87)
resistant 196 45 (23) 151 (77)
*
Based on Clinical and Laboratory Standards Institute guidelines
†
Based on European Committee on Antimicrobial Susceptibility Testing





















n 160 30 (19) 130 (81)
Any in vitro active drug in
first 7 days
aminoglycoside 70 (44) 11 (37) 59 (45) 0.42
colistin 27 (17) 5 (17) 22 (17) 1.00
tigecycline 76 (48) 20 (67) 56 (43) 0.03
trimethoprim/sulfamethoxazole 14 (9) 1 (3) 13 (10) 0.47
fosfomycin 17 (11) 7 (23) 10 (8) 0.02
Base of regimen
aminoglycoside 70 (44) 11 (37) 59 (45) 0.42
colistin 22 (14) 3 (10) 19 (15) 0.77
tigecycline 49 (31) 14 (47) 35 (27) 0.047
other 19 (12) 2 (7) 17 (13) 0.53
>1 in vitro active drug in first
7 days 42 (26) 13 (43) 29 (22) 0.02
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Table 4
Multivariable logistic regression for CRKP readmission in treated patients (n=160)
OR 95% CI p
Black race 1.69 0.68-4.23 0.26
History of malignancy 4.07 1.14-14.45 0.03
Renal failure 1.10 0.37-3.05 0.86
Base of regimen 0.02




>1 in vitro active drug in first 7 days 5.14 1.78-16.41 <0.01
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Table 5
Cox proportional hazards model on time to CRKP readmission within 90 days in treated 
patients (n=160)
aHR 95% CI p
Black race 1.93 0.85-4.30 0.12
Malignancy 3.17 1.12-7.83 0.03
Renal failure 1.06 0.41-2.46 0.88
Base of regimen 0.02




>1 in vitro active drug in first
7 days
4.46 1.77-11.36 <0.01
aHR, adjusted hazard ratio: CI, confidence interval.
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